Senate Committee Advances Nominee for CDC Director Amid Concerns of Political Influence
The Senate Health, Education, Labor, and Pensions Committee moved forward with Dr. Erica Schwartz’s nomination to lead the Centers for Disease Control and Prevention (CDC). This decision resolved initial doubts about her ability to resist political interference. If confirmed by the full Senate, Schwartz would become the 22nd director of the CDC, tasked with defending Americans against preventable health threats.
Schwartz’s career includes medical and law degrees, work as a deputy surgeon general, and a leadership role in the U.S. Coast Guard. Despite initial skepticism during a Senate hearing led by Chairman Sen. Bill Cassidy, R-La., Schwartz gained Cassidy’s support after private discussions and consultations with her associates. Cassidy expressed confidence in Schwartz’s competency and her willingness to challenge unscientific directives.
The committee vote was split mostly along party lines. Senator Bernie Sanders, a Vermont independent, opposed her nomination, questioning whether appointees have the courage to confront anti-science stances within the Trump administration. The CDC has encountered instability since President Trump’s return to office impacted by significant staff departures and temporary leadership. Political appointees with limited public health expertise have filled senior positions, affecting staff morale.
Schwartz’s nomination in April brought cautious optimism from public health experts due to her background and selection by Trump rather than Health Secretary Robert F. Kennedy Jr., known for his anti-vaccine stance. Previously, Kennedy reversed his pledge not to alter vaccination recommendations for children, prompting legal action from a federal judge that temporarily halted some efforts.
During the hearing, Cassidy and other senators pressed Schwartz on her response to unscientific demands from political appointees. Schwartz emphasized her commitment to science but hesitated to fully oppose Kennedy’s actions. The National Public Health Coalition, representing current and former CDC employees, expressed concern and urged clear commitments from Schwartz to uphold scientific integrity and vaccine policy.
Questions arose regarding Schwartz’s awareness of CDC program cuts, including those that focus on smoking prevention and vaccination promotion. She agreed that medical evidence does not link vaccines to autism but avoided pledging action to remove misleading CDC website content. As a gesture of good faith, a page modification occurred, yet continued controversy exists regarding the claim that ‘vaccines do not cause autism.’
Dr. Georges Benjamin, of the American Public Health Association, acknowledged Schwartz’s attempt to balance conflicting interests, expressing his continued support for her nomination. He emphasized her qualifications to rebuild the CDC’s structure and foster public trust by addressing bipartisan issues like foodborne illness outbreaks. Without Schwartz, the CDC risks continued leadership uncertainty, as observed by Dr. Daniel Jernigan, a former top official who resigned.
Schwartz’s nomination marks the third attempt under President Trump to secure a CDC leader in 18 months. Previously, nominee Dr. David Weldon’s Senate hearing was canceled due to insufficient support, while Susan Monarez faced dismissal after Senate confirmation due to policy disagreements with the administration. The CDC has since operated under interim leaders.
In addition to Schwartz, the committee approved a contentious nominee, Sean Kaufman, for assistant health secretary for preparedness and response. Concerns arose from Kaufman’s support of vaccine skepticism and mRNA vaccine cancellation. Cassidy warned of Kaufman’s previous irresponsible statements on immunization but noted that future responsibilities limit his influence on vaccine policy. The nomination process reflects ongoing leadership challenges within federal health agencies, as voiced by Sanders, who seeks better representation for the American public.